First-Line Treatment for Obstructive Sleep Apnea (OSA)

Primary Treatment Recommendations

The American Academy of Sleep Medicine recommends CPAP as the initial therapy for patients diagnosed with OSA, based on moderate-quality evidence 1, 2
CPAP effectively alleviates airway obstruction during sleep by delivering compressed air into the airway to keep it open 2
CPAP has demonstrated improvements in excessive sleepiness (strong recommendation), sleep-related quality of life, and comorbid hypertension (conditional recommendations) 3, 4
The American College of Physicians recommends that all overweight and obese patients diagnosed with OSA should be encouraged to lose weight as part of their treatment plan, despite being based on low-quality evidence 1, 2

Mandibular Advancement Devices (MADs) are recommended as an alternative therapy for patients who prefer these devices over CPAP, experience adverse effects with CPAP, or cannot tolerate CPAP therapy 1, 2, 5, 6
Evidence supports the use of MADs particularly in mild to moderate OSA, although this is a weak recommendation based on low-quality evidence 5, 6
The European Respiratory Society suggests considering maxillomandibular osteotomy for selected patients, and positional therapy, though it's clearly inferior to CPAP and has poor long-term compliance 5, 6
Hypoglossal nerve stimulation is an emerging therapy for OSA, according to the European Respiratory Review 7, 8

The American Academy of Sleep Medicine recommends that CPAP therapy can be initiated using either auto-adjusting PAP (APAP) at home or in-laboratory PAP titration 3, 4
Both CPAP and APAP are recommended for ongoing treatment of OSA, with educational interventions, behavioral and troubleshooting interventions, and telemonitoring-guided interventions to optimize adherence 3, 4

Treatment should be based on a diagnosis established using objective sleep apnea testing, with adequate follow-up, troubleshooting, and monitoring of efficacy and usage data 3, 4
The heterogeneous pathophysiology of OSA may require consideration of multiple factors when selecting therapy, according to the European Respiratory Review 7, 8
Patients with significant comorbidities may require special consideration when initiating PAP therapy, as recommended by the American Academy of Sleep Medicine 3, 4

The American Academy of Sleep Medicine recommends AutoPAP (APAP) as a first-line therapy for obstructive sleep apnea, which automatically adjusts airway pressure levels throughout the night, and can be initiated either at home or through an in-laboratory sleep study titration with equal effectiveness for patients without significant comorbidities 9, 10, 11

The American Academy of Sleep Medicine strongly recommends that PAP therapy (including APAP) can be initiated using either APAP at home or in-laboratory PAP titration, showing no clinically significant differences in treatment adherence, reduction in sleepiness, and improvement in quality of life 9, 10, 11

APAP is not recommended for patients with certain comorbidities, including congestive heart failure 11, chronic opiate use 10, neuromuscular disease 10, history of uvulopalatopharyngoplasty 10, oxygen requirements during sleep 10, and central sleep apnea syndromes 10, 11
For optimal results, APAP initiation should include proper mask fitting 10, education on PAP use 10, and close follow-up by trained staff 10, 11

Objective monitoring of efficacy and usage data is essential following PAP therapy initiation, and educational interventions at therapy initiation are strongly recommended to improve adherence 9, 12
Telemonitoring-guided interventions can help improve initial therapy adherence 12

APAP has been shown to effectively reduce impaired sleep-related quality of life 9, and comorbid hypertension 9, 12

The American Academy of Sleep Medicine recommends custom, titratable mandibular advancement devices (MADs) as the primary alternative for patients who cannot tolerate CPAP, with moderate improvement in quality of life outcomes 13
The American Academy of Sleep Medicine suggests that MADs reduce apnea-hypopnea index (AHI), arousal index, oxygen desaturation index, and increase oxygen saturation, though CPAP remains superior in these metrics 13
The European Respiratory Society provides a conditional recommendation against hypoglossal nerve stimulation as first-line treatment, but supports its use as second-line therapy after CPAP failure, for patients with AHI 15-65/h and BMI <32 kg/m² 14
Maxillomandibular advancement surgery can be considered for severe OSA patients who cannot tolerate or are not appropriate candidates for other recommended therapies, with similar efficiency to CPAP in patients who refuse conservative treatment 14

The American Academy of Sleep Medicine advises against prescribing custom non-titratable oral appliances, recommending only custom titratable devices with adequate evidence 13